This marks the first regulatory clearance for the R21/Matrix-M malaria vaccine for use in any country. The successful registration was notified to the Serum Institute of India Pvt Ltd (SIIPL) by the Food and Drugs Authority Ghana. SIIPL is the manufacturing and commercialisation license holder for the vaccine. The vaccine has been approved for use in children aged 5 to 36 months, the age group at the highest risk of death from malaria. It is hoped that this first crucial step will enable the vaccine to help Ghanaian and African children effectively combat malaria. The R21/Matrix-M™ vaccine has demonstrated high levels of efficacy and safety in Phase II trials, including amongst children who received a booster dose of++ R21/Matrix-M at one year following a primary three-dose regime.
‘This marks a culmination of 30 years of malaria vaccine research at Oxford with the design and provision of a high-efficacy vaccine that can be supplied at an adequate scale to the countries who need it most. I congratulate our superb clinical trial partners in Africa who have generated the dataset supporting the safety and efficacy of the vaccine in children. As with the Oxford-AstraZeneca COVID-19 vaccine, our partnership with the Serum Institute of India has been key to successful very large-scale manufacturing and rapid development.’
The R21/Matrix-MTM malaria vaccine is a low-dose vaccine that can be manufactured at a mass scale and modest cost, enabling as many as hundreds of millions of doses to be supplied to African countries which are suffering a significant malaria burden.
This vaccine was initially designed and developed at the University and has undergone clinical trials in the UK, Thailand, and several African countries, including an ongoing phase III trial in Burkina Faso, Kenya, Mali and Tanzania that has enrolled 4,800 children. Results from these trials are expected to be reported later this year.
The University researchers and their partners last year reported from a Phase IIb trial that a booster dose of R21/Matrix-M at one year following a primary three-dose regime maintained high efficacy against malaria, and continued to meet the World Health Organization’s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy. This followed 2021 results from the Phase-IIb trial reporting that R21/Matrix-M™ demonstrated high-level efficacy of 77%. Recent data from the large phase III trial also show high levels of efficacy and a reassuring safety profile.
The vaccine contains Novavax’s (Nasdaq: NVAX) Matrix-MTM, a saponin-based adjuvant that enhances the immune system response, making it more potent and more durable. The Matrix-M adjuvant stimulates the entry of antigen-presenting cells at the injection site and enhances antigen presentation in local lymph nodes. This technology has also been used successfully in Novavax’s COVID-19 vaccine and is a key component of other development-stage vaccines.
Notably, SIIPL has provided vaccines and sponsored Phase III licensure clinical trials, demonstrating its commitment to combatting malaria. SIIPL has already established potential manufacturing capacities of more than 200 million doses annually. The Serum Institute is also exploring collaborations to enable future manufacturing in Africa. Licensure applications are also in progress with other African countries as well as a WHO review for pre-qualification and a policy recommendation.
This breakthrough is a critical step towards reducing over half a million malaria-related deaths annually and improving the health outcomes of millions of people in Africa and beyond.
Adar Poonawalla, CEO of the Serum Institute of India Pvt Ltd., said:
‘Malaria is a life-threatening disease that disproportionately affects the most vulnerable populations in our society and remains a leading cause of death in childhood. Developing a vaccine to greatly impact this huge disease burden has been extraordinarily difficult. At the Serum Institute of India, we are committed to our vision of Health for All and ensuring equitable access to vaccines for people around the world.
‘The licensure of the R21/Matrix-M Malaria Vaccine for use in Ghana is a significant milestone in our efforts to combat malaria around the world. We remain steadfast in our commitment to scaling up production of the vaccine to meet the needs of countries with high malaria burden and to support global efforts towards saving lives.’
John C. Jacobs, President and Chief Executive Officer, Novavax said:
‘We’re thrilled that Novavax’s Matrix-M™ adjuvant has contributed to the success of this promising and much-needed malaria vaccine. We intend to further leverage the robust and beneficial technology behind our adjuvant to bring more life-saving vaccines to market.’
The design and development of R21/Matrix-M have been supported by funding awards to the University of Oxford and partners from the European Commission, the European and Developing Countries Clinical Trials Partnership, UK Research and Innovation, The Wellcome Trust, the UK National Institute for Health and Care Research, the Bill and Melinda Gates Foundation and the Serum Institute of India Pvt Ltd.